FCE 26743

Known as: FCE-26743 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
  • 2018
BIOLOGICAL ACTIVITY: Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits… (More)
Is this relevant?
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
Safinamide [NW 1015, PNU 151774E; FCE 26743] is a potent anticonvulsant and antiparkinsonian compound that is being developed by… (More)
Is this relevant?
2002
2002
 Several compounds with antagonistic actions on N-methyl-D-aspartate (NMDA) receptors were tested for an antiakinesic action in… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
1999
1999
The effects of co-administration of the dopamine precursor, L-Dopa, with anticonvulsant and putative anticonvulsive agents upon… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1994
1994
The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase… (More)
Is this relevant?